Mitchel L. Zoler, PhD
![1]()
News
No link shown between thyroid dysfunction and heart failure
November 10, 2020
Analysis of nearly 5,000 English heart failure patients showed no significant link between thyroid dysfunction and survival.
News
Entresto halves renal events in preserved EF heart failure patients
October 15, 2020
The PARAGON-HF trial of sacubitril/valsartan in patients with heart failure with preserved ejection fraction didn’t meet its primary outcome but significantly improved a secondary renal endpoint.
![1]()
News
Empagliflozin cut PA pressures in heart failure patients
October 12, 2020
The drops in pulmonary artery pressure were modest but large enough to be clinically meaningful, they appeared quickly, and increased over time.
![1]()
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan
October 6, 2020
Empagliflozin treatment of HFrEF was equally beneficial regardless of whether patients also received sacubitril/valsartan.
![1]()
News
Dapagliflozin’s CKD performance sends heart failure messages
October 5, 2020
The recently reported DAPA-CKD trial results focused on patients with renal disease, but the findings also resonate for heart failure clinicians.
![1]()
News
DAPA-CKD resets eGFR floor for safe SGLT2 inhibitor use
September 25, 2020
Until now, SGLT2 inhibitors were for patients with an eGFR of at least 30 mL/min per m2. New evidence moves the threshold down to 25.
![1]()
News
ESC’s revised NSTE-ACS guidelines embrace hsT, personalized anti-ischemia treatments
August 31, 2020
The first guideline update in 5 years for non ST-elevation ACS stresses high sensitivity troponin for diagnosis and tailored antiplatelet treatments.
![1]()
News
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
August 31, 2020
DAPA-CKD showed that dapagliflozin helps patients with albuminuria and declining eGFR levels whether or not they have type 2 diabetes.
![1]()
News
EMPEROR-Reduced: Empagliflozin’s HFrEF benefit solidifies class effects
August 30, 2020
The 25% cut in primary endpoints among HFrEF patients on empagliflozin matched the benefit seen before from dapagliflozin in DAPA-HF.
![1]()
News
Cleaner data confirm severe COVID-19 link to diabetes, hypertension
July 27, 2020
Initial reports that tied more severe COVID-19 disease to diabetes or hypertension used confounded data, but more refined data show similar links.
